Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Pharma
AstraZeneca's Truqap falls short in another phase 3 trial
AstraZeneca has come up short in another phase 3 trial of Truqap, raising more questions about the blockbuster potential of the first-in-class drug.
Kevin Dunleavy
Apr 29, 2025 3:26pm
Novartis' Pluvicto wins key FDA nod toward $5B-plus sales target
Mar 28, 2025 3:02pm
Novartis pumps $7.5M into push to save 100,000 lives by 2035
Feb 19, 2025 8:40am
Pfizer details survival win in bid for broad prostate cancer nod
Feb 13, 2025 10:00am
AZ's Truqap carves path in prostate cancer with phase 3 win
Nov 25, 2024 11:12am
Novartis complies with FDA 'flexibility' ask in Pluvicto filing
Oct 29, 2024 10:51am
